HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Activist Investor May Push P&G To Sell Non-Core Brands, Oust CEO McDonald

This article was originally published in The Tan Sheet

Executive Summary

Changes may be ahead for Procter & Gamble following William Ackman and Pershing Square Capital Management’s investment in the consumer products giant. Analysts suggest the activist investor may push to replace CEO Bob McDonald and divest non-core brands.

You may also be interested in...



P&G Slashes Guidance, Promises Sharper Focus, Bigger Innovations

The firm makes “necessary adjustments” to achieve more balanced growth across its markets and product categories, CEO Bob McDonald says. But Wall Street may not be reassured, as analysts are frustrated with P&G for not better defending against macroeconomic challenges and fixing internal structural issues.

Procter & Gamble CEO McDonald Takes Heat For Sagging Earnings

Recent struggles cause Procter & Gamble to knock down its full-year earnings-per-share guidance. The firm has lost share in U.S. oral care, where it faces “unprecedented” promotional spending by competitors.

PGT Healthcare Aims To Unlock Value Of Existing Portfolios

PGT Healthcare CEO Briain de Buitleir and COO Eli Shani say the joint venture will help Teva realize greater value for its localized OTCs and enable Procter & Gamble to expand its nutritional products portfolio.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel